| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | 乳汁中の大腸菌群を検出する方法 | JP2015553591 | 2014-12-17 | JP6280567B2 | 2018-02-14 | 前花 浩志; 松山 健二 |
| 22 | 乳汁中の大腸菌群を検出する方法 | JP2015553591 | 2014-12-17 | JPWO2015093545A1 | 2017-03-23 | 浩志 前花; 松山 健二; 健二 松山 |
| 家畜の乳汁を用いて乳房炎の原因菌が大腸菌群であるか否かを検出するための溶菌方法、溶菌処理液およびイムノクロマト装置からなる検出方法および検出キットを提供することを課題とする。大腸菌群の溶菌方法であって、家畜から得た乳汁に、溶菌酵素および少なくとも一の陰イオン界面活性剤、好ましくはさらに少なくとも一の非イオン界面活性剤を含有する溶菌剤を混合して乳汁中に存在する大腸菌群を溶菌する工程を含む方法を提供する。溶菌酵素は、好ましくはリゾチームである。 | ||||||
| 23 | 織物への微生物付着を低減する方法 | JP2016559683 | 2014-12-18 | JP2017503092A | 2017-01-26 | ハインツ・カッツェンマイヤー; ペーター・シュッテ; サブリーナ・シュミットエムリヒ; リンダ・テーニー−マイヤー; グン・レン・ツリアン |
| 本発明は、繊維及び/又は織物を仕上げる方法に関し、企図するところは、繊維及び/又は織物への微生物、特に細菌及び/又は酵母の付着を低減することにある。開示したこの方法は、選択された親水性のシラン誘導体を含む組成物(ZS)を繊維及び/又は織物に適用することを含む。本発明はさらに、繊維及び/又は織物への微生物の付着を定量的に測定する方法に関する。 | ||||||
| 24 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 | JP2016525434 | 2014-07-08 | JP2016530239A | 2016-09-29 | 賢也 本田; オーレ、バーナット; 幸二 新; 大 田之上; 大野 博司; 博司 大野; 真嗣 福田; 耕二 長谷 |
| 哺乳動物の微生物叢由来生物活性分子から成る組成物が、本明細書中で提供される。該組成物は、結腸送達システムを伴って経口投与される場合、疾患、特に炎症性疾患、自己免疫疾患及び感染性疾患の予防及び治療に有用である。該組成物は、結腸送達システムで製剤化された小分子及び細菌性抗原の組み合わせを含む。該組成物の使用により:免疫寛容の誘導;腸管粘膜バリアの完全性の強化;炎症の低減;及び炎症、自己免疫反応又は感染性因子によって惹起された疾患状態の緩和のいずれか或いはすべてがもたらされる。【選択図】図4−1 | ||||||
| 25 | がん治療のための予測的バイオマーカー | JP2016515715 | 2014-05-15 | JP2016526164A | 2016-09-01 | シュロフ，マティアス; シュミット，マヌエル; カップ，カースチン; ヴィティヒ，ブルクハルト |
| 本発明は一般に、がんに冒された患者が特定の治療に応答するか否かを同定することに関する。より具体的には、本発明はTLR−9アゴニスト療法の応答者を同定するための方法および手段に関する。 | ||||||
| 26 | インフルエンザにおけるリスクの階層化 | JP2015520775 | 2013-07-10 | JP2015530868A | 2015-10-29 | アンソニー マックリーン; ベンジャミン タン; グラント ピーター パーネル; マリアム ショジャエイ |
| 本発明は、インフルエンザを有するまたは有することが疑われる患者における臨床的リスクを同定するための方法に関する。本発明はまた、インフルエンザまたはウイルス性肺炎を有する患者を、症状が類似の状態を有する患者と区別するための方法にも関する。本発明の方法は、インフルエンザを有するまたは有することが疑われる患者由来の生物試料中のインターフェロンα誘導タンパク質27(IFI27)の発現レベルの決定を含む。本方法を実行するための適した成分を含むキットもまた、本発明によって提供される。本発明によって、臨床的リスクを定義する群、たとえば対象の長期の健康に対するリスクの重症度に基づく群に、患者を階層化することができる。 | ||||||
| 27 | 表面プラズモン共鳴分析用微細構造チップ、前記微細構造チップを含む分析装置、および前記装置の使用 | JP2014537696 | 2012-10-25 | JP2014531038A | 2014-11-20 | メルセー，ティボー |
| 本発明は、表面プラズモン共鳴(SPR)分析用微細構造チップに関し、これは底面と、少なくとも一部が金属層で被覆された上面と、少なくとも1つの側面と、により形成される固体の形態をとる。このチップは、上記の上面(4、44)に、分析対象の種を受けるように意図された少なくとも2つのマイクロメートルレベルの領域が、少なくとも1つのキャビティおよび/または少なくとも1つの突起(1、11、41、51、61)の何れかから設けられ、前記領域は平面によって相互から分離され、前記領域の少なくとも1つがそれ以外のものと異なることを特徴とする。【選択図】図3 | ||||||
| 28 | Monoclonal antibodies capable of reacting with multiple subtypes of influenza a virus | JP2011500336 | 2009-03-16 | JP5542118B2 | 2014-07-09 | ロベルト・ブリオーニ; マッシモ・クレメンティ |
| 29 | AVIAN REOVIRUS VACCINES | US15959503 | 2018-04-23 | US20180236061A1 | 2018-08-23 | Holly S. Sellers |
| The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses. | ||||||
| 30 | Risk stratification in influenza | US14410367 | 2013-07-10 | US10036075B2 | 2018-07-31 | Anthony McLean; Benjamin Tang; Grant Peter Parnell; Maryam Shojaei |
| The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IF127) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject. | ||||||
| 31 | Method for diagnosing tuberculosis disease by detecting induced markers after stimulation of T-cells with antigens | US14403659 | 2013-05-27 | US10001481B2 | 2018-06-19 | Gerhard Walzl; Novel Njweipi Chegou; Paulin Essone Ndong |
| A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-α, TNF-α, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-α2, fractalkine, IFN-γ, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1α, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1β, IL-6, GM-CSF, IL-1α, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-β, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject. | ||||||
| 32 | NONWOVEN ARTICLES FOR DETECTING MICROORGANISMS IN A FLUID SAMPLE AND METHODS OF USING THE NONWOVEN ARTICLES | US15558300 | 2016-03-17 | US20180059108A1 | 2018-03-01 | Manjiri T. Kshirsagar; Raj Rajagopal |
| Nonwoven articles for detecting microorganisms or cellular analytes in a fluid sample are provided. The nonwoven article includes a fibrous porous matrix and concentration agent particles enmeshed in the fibrous porous matrix. The fibrous porous matrix generally consists of inorganic fibers and polymeric fibers. Methods of detecting microorganisms or cellular analytes in a fluid sample are also provided. The method includes providing the nonwoven article, providing a fluid sample suspected of containing at least one microorganism strain or target cellular analyte, contacting the fluid sample with the nonwoven article such that at least a portion of the at least one microorganism strain or target cellular analyte is bound to the nonwoven article, and detecting the presence of bound microorganism strain(s) or bound cellular analyte(s). | ||||||
| 33 | IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAE | US15547299 | 2016-01-27 | US20180002407A1 | 2018-01-04 | Kenji SAITO |
| The present invention aims at providing a specific antibody that can simply and rapidly detect Mycoplasma pneumoniae which is a causative bacterium of mycoplasma pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with Mycoplasma pneumoniae more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of Mycoplasma pneumoniae and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques. | ||||||
| 34 | TARGET CAPTURE SYSTEM | US15463385 | 2017-03-20 | US20170226564A1 | 2017-08-10 | Ravil A. Sitdikov; Eddie W. Adams; Magdalena A. Torrance; David K. Aley; Erik J. Smith; Victor C. Esch |
| The invention generally relates to a system for isolating or separating a target from a sample. In certain aspects, processes performed by the target capture system include introducing a plurality of magnetic particles, in which a plurality of the particles include at least one binding moiety specific to a target, into a sample to form at least one target/particle complex and applying a magnetic field to isolate the magnetic particle/target complexes from the sample. The process starts at inputting a sample into the system and ends at delivering a capture target or nucleic acids of the target into a container for further analysis. | ||||||
| 35 | Eukaryotic cells with artificial endosymbionts for multimodal detection | US15263144 | 2016-09-12 | US09657358B2 | 2017-05-23 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 36 | Monoclonal Antibodies Capable of Reacting with a Plurality of Influenza Virus A Subtypes | US15083584 | 2016-03-29 | US20160200801A1 | 2016-07-14 | Roberto Burioni; Massimo Clementi |
| Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines. | ||||||
| 37 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | US14903377 | 2014-07-08 | US20160144014A1 | 2016-05-26 | Kenya Honda; Bernat Olle; Koji Atarashi; Takeshi Tanoue; Hiroshi Ohno; Shinji Fukuda; Koji Hase |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
| 38 | Monoclonal Antibodies Capable of Reacting with a Plurality of Influenza Virus a Subtypes | US14938101 | 2015-11-11 | US20160060325A1 | 2016-03-03 | Roberto Burioni; Massimo Clementi |
| Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines. | ||||||
| 39 | AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS | US14804383 | 2015-07-21 | US20160025603A1 | 2016-01-28 | Thomas J. Kindt; John F. Steel |
| Air flow systems, devices and methods for monitoring airborne agents include airborne agent collectors. Airborne agent collectors for collecting and detecting the presence and/or identification of an airborne agent(s) include a soluble and hydrophilic polycaprolactone (PCL) that has been treated with a base (e.g., a base having a pH greater than 8 (e.g., NaOH, NaHCO3, KOH, Na2CO3, and CA(OH)2) and in some embodiments, also treated with a neutralizing agent for increasing hydrophilicity. Detection and identification of airborne agents captured by an airborne agent collector can be performed using any suitable analytical protocols. Such protocols are well known in the art, and include nucleic acid assays, protein assays (e.g., mass spectrometry), and bioassays (e.g., in vitro and in vivo assays). The airborne agent collectors can be used for the detection and identification of nucleic acid from cells or organisms of any type (e.g., viruses, bacteria, fungi) in fixed structures (e.g., homes, sports arenas, theaters, buildings such as offices, laboratories, hospitals, schools, airports, train stations, bus stations, etc.) and in mobile, portable devices or machines (e.g., aircraft, automobiles, air-freshener, air-purifier, air re-circulator, vacuum cleaner, etc.). | ||||||
| 40 | Method for Diagnosing Tuberculosis Disease by Detecting Induced Markers After Stimulation of T-Cells With Antigens | US14403659 | 2013-05-27 | US20150141279A1 | 2015-05-21 | Gerhard Walzl; Novel Njweipi Chegou; Paulin Essone Ndong |
| A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-α, TNF-α, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-α2, fractalkine, IFN-γ, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1α, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1β, IL-6, GM-CSF, IL-1α, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-β, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject. | ||||||
QQ群二维码
意见反馈
意见反馈